ZA782648B
(en)
*
|
1977-05-23 |
1979-06-27 |
Ici Australia Ltd |
The prevention,control or eradication of infestations of ixodid ticks
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
DE69222637T2
(de)
|
1991-05-10 |
1998-02-26 |
Rhone Poulenc Rorer Int |
Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
CA2148484A1
(en)
|
1992-11-13 |
1994-05-26 |
Stewart Lyman |
Novel cytokine designated elk ligand
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
CA2148931A1
(en)
|
1993-10-01 |
1995-04-13 |
Jurg Zimmermann |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
CA2175215C
(en)
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
CN1046944C
(zh)
|
1993-12-17 |
1999-12-01 |
山道士有限公司 |
雷怕霉素类衍生物
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
WO1995028484A1
(en)
|
1994-04-15 |
1995-10-26 |
Amgen Inc. |
Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
|
ATE159257T1
(de)
|
1994-05-03 |
1997-11-15 |
Ciba Geigy Ag |
Pyrrolopyrimidinderivate mit antiproliferativer wirkung
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
ATE446955T1
(de)
|
1995-03-30 |
2009-11-15 |
Pfizer Prod Inc |
Chinazolinone derivate
|
JP4249804B2
(ja)
|
1995-04-03 |
2009-04-08 |
ノバルティス・アクチエンゲゼルシャフト |
ピラゾール誘導体およびその製造法
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
CA2219659C
(en)
|
1995-06-09 |
2008-03-18 |
Novartis Ag |
Rapamycin derivatives
|
DE69619114T2
(de)
|
1995-07-06 |
2002-10-02 |
Novartis Ag |
Pyrolopyrimidine und verfahren zu ihrer herstellung
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DK0780386T3
(da)
|
1995-12-20 |
2003-02-03 |
Hoffmann La Roche |
Matrixmetalloproteaseinhibitorer
|
EP0888349B1
(en)
|
1996-01-23 |
2002-05-22 |
Novartis AG |
Pyrrolopyrimidines and processes for their preparation
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DK0888353T3
(da)
|
1996-03-15 |
2003-10-27 |
Novartis Ag |
N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse
|
NZ332119A
(en)
|
1996-04-12 |
2001-08-31 |
Warner Lambert Co |
Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
BR9709959A
(pt)
|
1996-06-24 |
2000-05-09 |
Pfizer |
Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
AU735648B2
(en)
|
1996-07-12 |
2001-07-12 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
ID19430A
(id)
|
1996-07-13 |
1998-07-09 |
Glaxo Group Ltd |
Senyawa senyawa heterosiklik
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
TR199900066T2
(xx)
|
1996-07-18 |
1999-04-21 |
Pfizer Inc. |
Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
|
ATE397660T1
(de)
|
1996-08-16 |
2008-06-15 |
Schering Corp |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
IL128189A0
(en)
|
1996-08-23 |
1999-11-30 |
Pfizer |
Arylsulfonylamino hydroxamic acid derivatives
|
PT938486E
(pt)
|
1996-08-23 |
2008-03-27 |
Novartis Ag |
Pirrolopirimidinas substituídas e processos para a sua preparação
|
WO1998014450A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
WO1998014449A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
US6077864A
(en)
|
1997-01-06 |
2000-06-20 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
PL335027A1
(en)
|
1997-02-03 |
2000-03-27 |
Pfizer Prod Inc |
Derivatives of arylsulphonylamino hydroxamic acid
|
DE69839338T2
(de)
|
1997-02-05 |
2008-07-10 |
Warner-Lambert Company Llc |
Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
|
CA2279863A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
BR9807678A
(pt)
|
1997-02-11 |
2000-02-15 |
Pfizer |
Derivados de ácidos arilsulfonil-hidroxâmicos
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
AU8689298A
(en)
|
1997-08-05 |
1999-03-01 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
KR100372138B1
(ko)
|
1997-08-08 |
2003-02-14 |
화이자 프로덕츠 인코포레이티드 |
아릴옥시아릴설포닐아미노 하이드록삼산 유도체
|
AU1102399A
(en)
|
1997-10-21 |
1999-05-10 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
SK6652000A3
(en)
*
|
1997-11-11 |
2002-05-09 |
Pfizer Prod Inc |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
CA2319236A1
(en)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
EP1066286B1
(en)
|
1998-03-04 |
2009-04-29 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
IL139934A
(en)
|
1998-05-29 |
2007-10-31 |
Sugen Inc |
History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
JP2002520324A
(ja)
|
1998-07-10 |
2002-07-09 |
メルク エンド カムパニー インコーポレーテッド |
新規な血管形成インヒビター
|
EP1109555A4
(en)
|
1998-08-31 |
2001-11-21 |
Merck & Co Inc |
NEW ANGIOGENIC INHIBITORS
|
PT1004578E
(pt)
|
1998-11-05 |
2004-06-30 |
Pfizer Prod Inc |
Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
|
EP1165085B1
(en)
|
1999-03-30 |
2006-06-14 |
Novartis AG |
Phthalazine derivatives for treating inflammatory diseases
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
DK1187918T4
(da)
|
1999-06-07 |
2009-02-23 |
Immunex Corp |
TEK-antagonister
|
DE60036945T2
(de)
|
1999-07-12 |
2008-08-21 |
Genentech, Inc., South San Francisco |
Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
|
AU783158B2
(en)
|
1999-08-24 |
2005-09-29 |
Ariad Pharmaceuticals, Inc. |
28-epirapalogs
|
EE05330B1
(et)
|
1999-11-05 |
2010-08-16 |
Astrazeneca Ab |
Kinasoliini derivaadid kui VEGF-i inhibiitorid
|
ATE514676T1
(de)
|
1999-11-24 |
2011-07-15 |
Sugen Inc |
Ionisierbare indolinon derivate und deren verwendung als ptk liganden
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
ES2302726T3
(es)
|
2000-02-24 |
2008-08-01 |
Invitrogen Corporation |
Estimulacion y concentracion simultanea de celulas.
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
NZ521437A
(en)
|
2000-02-25 |
2004-04-30 |
Immunex Corp |
Integrin antagonists suitable as inhibitors of angiogenesis
|
JP2002105081A
(ja)
*
|
2000-07-28 |
2002-04-10 |
Nikken Chem Co Ltd |
新規チオフェンニ環化合物
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
WO2002026745A1
(fr)
*
|
2000-09-29 |
2002-04-04 |
Nippon Soda Co., Ltd. |
Composes de thienopyrimidine et leurs sels et procede de preparation
|
IL156306A0
(en)
|
2000-12-21 |
2004-01-04 |
Glaxo Group Ltd |
Pyrimidineamines as angiogenesis modulators
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
AU2002364211A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
US20050026868A1
(en)
|
2003-07-11 |
2005-02-03 |
Metcalf Chester A. |
Phosphorus-containing macrocycles
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
RU2369636C2
(ru)
|
2003-05-23 |
2009-10-10 |
Уайт |
Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
|
CA2531454C
(en)
|
2003-07-08 |
2011-10-25 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
GB0320300D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Cancer Rec Tech Ltd |
Pyrimidothiophene compounds
|
WO2005055808A2
(en)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions and methods to diagnose and treat lung cancer
|
US20080058431A1
(en)
|
2004-03-26 |
2008-03-06 |
Gen-Sheng Feng |
Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
DK1786785T3
(da)
|
2004-08-26 |
2010-05-31 |
Pfizer |
Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
|
PE20060608A1
(es)
|
2004-10-13 |
2006-08-22 |
Wyeth Corp |
Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
|
BRPI0516242B1
(pt)
*
|
2004-10-21 |
2014-10-07 |
Dow Agrosciences Llc |
Compostos tieno-pirimidina com atividade fungicida, bem como composição fungicida e método para o controle ou prevenção de ataque fúngico
|
PT1866339E
(pt)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Moléculas de ligação a gitr e suas utilizações
|
KR101339628B1
(ko)
|
2005-05-09 |
2013-12-09 |
메다렉스, 인코포레이티드 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20090012085A1
(en)
|
2005-09-20 |
2009-01-08 |
Charles Michael Baum |
Dosage forms and methods of treatment using a tyrosine kinase inhibitor
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
US8987474B2
(en)
|
2006-04-07 |
2015-03-24 |
University Of South Florida |
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
|
CL2007003520A1
(es)
|
2006-12-07 |
2008-08-22 |
Piramed Ltd Genentech Inc |
Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
|
WO2008124815A1
(en)
|
2007-04-10 |
2008-10-16 |
University Of South Florida |
Method of activating nk cells
|
WO2009009116A2
(en)
|
2007-07-12 |
2009-01-15 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
KR101584823B1
(ko)
|
2007-09-12 |
2016-01-22 |
제넨테크, 인크. |
포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
|
WO2009049098A2
(en)
|
2007-10-09 |
2009-04-16 |
Indiana University Research & Technology Corporation |
Materials and methods for regulating the activity of phosphatases
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
WO2009135000A2
(en)
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
US20110177070A1
(en)
|
2008-07-02 |
2011-07-21 |
Emergent Product Development Seatlle, LLC |
TGF-Beta Antagonist Multi-Target Binding Proteins
|
WO2010011666A2
(en)
|
2008-07-21 |
2010-01-28 |
University Of South Florida |
Indoline scaffold shp-2 inhibitors and cancer treatment method
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
WO2010054285A2
(en)
*
|
2008-11-10 |
2010-05-14 |
National Health Research Institutes |
Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
ES2608670T3
(es)
|
2009-08-17 |
2017-04-12 |
Memorial Sloan-Kettering Cancer Center |
Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
|
IN2015DN02826A
(es)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
AU2010343056A1
(en)
|
2009-12-29 |
2012-08-02 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
US8637684B2
(en)
|
2010-05-12 |
2014-01-28 |
Wisconsin Alumni Research Foundation |
Tautomycetin and tautomycetin analog biosynthesis
|
WO2012041524A1
(en)
|
2010-10-01 |
2012-04-05 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
|
JP5961187B2
(ja)
*
|
2010-12-20 |
2016-08-02 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
|
EP2688887B1
(en)
|
2011-03-23 |
2015-05-13 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
US20150352131A1
(en)
|
2013-01-16 |
2015-12-10 |
Rhode Island Hospital |
Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
US9522881B2
(en)
|
2013-04-26 |
2016-12-20 |
Indiana University Research And Technology Corporation |
Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
|
CA2953482A1
(en)
|
2013-07-03 |
2015-01-08 |
Indiana University Research & Technology Corporation |
Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
|
WO2015000959A1
(en)
*
|
2013-07-03 |
2015-01-08 |
Norwegian University Of Science And Technology (Ntnu) |
4-amino-6-aryl[2,3-d]pyrimidines for the inhibition of egfr tyrosine kinase
|
EP2826586A1
(en)
|
2013-07-18 |
2015-01-21 |
Siemens Aktiengesellschaft |
A method and a system for machining an object
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
CN105418632B
(zh)
*
|
2014-09-19 |
2020-02-21 |
上海创诺医药集团有限公司 |
噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
|
WO2016077793A1
(en)
|
2014-11-14 |
2016-05-19 |
Children's Hospital Medical Center |
Sos1 inhibitors for cancer treatment
|
WO2016115434A1
(en)
*
|
2015-01-16 |
2016-07-21 |
The General Hospital Corporation |
Compounds for improving mrna splicing
|
US20180121597A1
(en)
|
2015-05-22 |
2018-05-03 |
Allosta Pharmaceuticals |
Methods to Prepare and Employ Binding Site Models for Modulation of Phosphatase Activity and Selectivity Determination
|
US10494332B2
(en)
|
2015-06-01 |
2019-12-03 |
Indiana University Research And Technology Corporation |
Protein tyrosine phosphatases or SHP2 inhibitors and uses thereof
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
US10975080B2
(en)
|
2015-06-19 |
2021-04-13 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
CN112625028A
(zh)
|
2015-06-19 |
2021-04-09 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
US11008372B2
(en)
|
2015-11-07 |
2021-05-18 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
WO2017100279A1
(en)
|
2015-12-09 |
2017-06-15 |
West Virginia University |
Chemical compound for inhibition of shp2 function and for use as an anti-cancer agent
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
CN109071567B
(zh)
*
|
2016-05-19 |
2021-03-23 |
四川大学 |
抗流感小分子化合物及其制备方法和用途
|
CA3024706A1
(en)
|
2016-05-31 |
2017-12-07 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of ptpn11
|
JP6751203B2
(ja)
|
2016-06-07 |
2020-09-02 |
ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. |
Shp2阻害剤として有用な新規複素環式誘導体
|
WO2018013597A1
(en)
|
2016-07-12 |
2018-01-18 |
Revolution Medicines, Inc. |
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
|
EP3558979B1
(en)
*
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
WO2018129402A1
(en)
|
2017-01-06 |
2018-07-12 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
RU2769132C2
(ru)
|
2017-01-10 |
2022-03-28 |
Новартис Аг |
Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
|
GB201700814D0
(en)
*
|
2017-01-17 |
2017-03-01 |
Liverpool School Tropical Medicine |
Compounds
|
BR112019014527A2
(pt)
|
2017-01-23 |
2020-02-27 |
Revolution Medicines, Inc. |
Compostos de piridina como inibidores de shp2 alostéricos
|
BR112019015075A2
(pt)
|
2017-01-23 |
2020-03-10 |
Revolution Medicines, Inc. |
Compostos bicíclicos como inibidores de shp2 alostéricos
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
CA3056970A1
(en)
*
|
2017-03-21 |
2018-09-27 |
Bayer Pharma Aktiengesellschaft |
2-methyl-quinazolines
|
NZ758458A
(en)
|
2017-03-23 |
2022-07-29 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
EP3619216A1
(en)
|
2017-05-02 |
2020-03-11 |
Revolution Medicines, Inc. |
Rapamycin analogs as mtor inhibitors
|
WO2019051084A1
(en)
|
2017-09-07 |
2019-03-14 |
Revolution Medicines, Inc. |
SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
|
WO2019051469A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
SHP2 OCTAHYDROCYCLOPENTA [C] PYRROLE ALLOSTERIC INHIBITORS
|
TW202014208A
(zh)
|
2018-05-01 |
2020-04-16 |
美商銳新醫藥公司 |
作為mTOR抑制劑之C40-、C28-及C-32連接之雷帕黴素類似物
|
AU2019262979B2
(en)
|
2018-05-01 |
2023-07-06 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mTOR inhibitors
|